Apellis Pharmaceuticals
Présence
Apellis Pharmaceuticals fait partie des...
Apellis Pharmaceuticals est une société cotée sous le symbole boursier APLS (US).
Dirigeants
Voir l'organigramme avec ses 24 principaux dirigeants
Biographies les plus recherchées chez Apellis Pharmaceuticals
- Cedric Francois, Chief Executive Officer and Director
- Gerald Chan, Chairman of the Board
- Alec Machiels, Director
Changements de dirigeants chez Apellis Pharmaceuticals
- Adam Townsend qui était Chief Commercial Officer, est promu Chief Operating Officer (publié le 23 janvier 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Apellis Pharmaceuticals.
Biotechnologie
Apellis Pharmaceuticals a 2 284 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Karius vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 3 mai 2024).
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Apellis Pharmaceuticals
- Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity | Apellis Pharmaceuticals, Inc.
- Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week | Apellis Pharmaceuticals, Inc.
- Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit | Apellis Pharmaceuticals, Inc.
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 | Apellis Pharmaceuticals, Inc.
- Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results | Apellis Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Apellis Pharmaceuticals
- Apellis Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Apellis Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
